Lupus & antiphospholipid syndrome

Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials

Lupus Sci MedPublished Systematic review and meta-analysis of randomised trials

Pooled result · New thrombotic events (any venous or arterial thrombosis)Result — go to the resultPeto OR 3.01 95% CI 1.56–5.78

Authors' conclusion

DOACs were associated with a significant increase in the risk of a new thrombotic event, especially AT, favouring standard prophylaxis with warfarin.

Study context

Population
Individuals >18 years with antiphospholipid syndrome (APS) classified according to the criteria valid when the trial was carried out
Participants
624 individuals5 randomised trials
Comparison
Direct oral anticoagulants (DOACs) vs vitamin K antagonists (VKAs) for secondary prevention of thromboembolic events in APS
Outcome
New thrombotic events, a composite of any venous or arterial thrombosis, during the VKA-controlled phase of treatment
Methodological detailsPeto method
  • Peto method

Pooled result

As reported in the abstract

New thrombotic events:
  • Any venous
  • Arterial thrombosis

Peto OR

3.01

95% CI 1.56–5.78

P = 0.001

Events by group

DOAC

29

events

VKA

10

events

DOACvs VKA
Peto OR 3.01 (95% CI 1.56–5.78); P = 0.001

Further pooled results

OutcomeOR (CI)P value
Arterial thrombosisDOACvs VKA5.5 (2.5–12.1)P < 0.0001
OutcomeP value
Venous thrombosisDOAC vs VKAP = 0.87

Venous thrombosis

No difference in risk of venous thrombosis (VT)

Safety

No significant difference in risk of bleeding

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials. Lupus Sci Med. Published 29 October 2023. doi:10.1136/lupus-2023-001018

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.